Every one of those 1 sits in a single category, fda-approval. mFLUSIVA (mRNA-1010) is most often covered alongside Moderna, Inc., which appears in 1 of these 1 story. We currently track 1 Biotech story that mention mFLUSIVA (mRNA-1010), all published on August 6, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about mFLUSIVA (mRNA-1010)
Every one of those 1 sits in a single category, fda-approval. mFLUSIVA (mRNA-1010) is most often covered alongside Moderna, Inc., which appears in 1 of these 1 story. We currently track 1 Biotech story that mention mFLUSIVA (mRNA-1010), all published on August 6, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering mFLUSIVA (mRNA-1010). Shared-story counts are live from our verified record — not editorial picks.
The U.S. FDA approved Moderna's mFLUSIVA, an mRNA seasonal influenza vaccine, for adults 50 and older. Data from two randomized trials, including a 40,805-subject Phase 3, supported the approval, with the 65+ cohort receiving accelerated approval. This milestone validates the mRNA platform beyond COVID-19 and positions Moderna to compete in the $5 billion+ global flu vaccine market.
